The continuous and rapid developments in imaging lead to refinements in our definition capabilities and decrease the need for invasive diagnostic procedures. While the biophysical technology is advancing in sophistication (and cost), there is a surprising stagnation in methods based on radioimmunoscintigraphy (RIS). Surprising, because the rationale for sensitivity and specificity of this approach is strong. The principle is deceivingly simple: an antibody directed against a cancer-specific antigen, usually located on or close to the surface of the malignant cell, is tagged with an isotope and detected with routinely established detector methodology. Why then, after almost fifty years of experiments and trials, has RIS remained a Cinderella among the diagnostic procedures in cancer?
Go to Previous Page
Go to Next Page